Group 1 - The core viewpoint of the news is the performance and holdings of the ICBC Frontier Medical Stock A fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1][3]. - As of June 10, 2025, the latest net value of ICBC Frontier Medical Stock A is 3.2190 yuan, with a growth of 0.72%. The fund has a one-month return of 13.03%, a three-month return of 18.65%, and a year-to-date return of 22.35% [1]. - The top ten holdings of the fund account for a total of 59.05%, with significant investments in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1]. Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan. The fund manager is Zhao Bei [1]. - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having served in various roles within ICBC Credit Suisse Asset Management since 2010 [2].

Core Viewpoint - The report highlights the performance and holdings of the Fuqua Precision Medical Mixed A Fund, showcasing its strong returns and key stock positions in the healthcare sector [1]. Fund Performance - The latest net value of Fuqua Precision Medical Mixed A is 3.2727 yuan, with a growth of 0.62% - The fund's one-month return is 18.98%, ranking 20 out of 2331 in its category - Over the past six months, the return is 35.63%, ranking 14 out of 2295 - Year-to-date, the return stands at 46.87%, ranking 12 out of 2306 [1]. Fund Holdings - The top ten stock holdings of Fuqua Precision Medical Mixed A account for a total of 69.71%, with the following key positions: - Baillie Gifford (9.66%) - Haisco (9.65%) - Kelun Pharmaceutical (9.10%) - Huatai Medical (9.05%) - Zai Lab (7.84%) - Hansoh Pharmaceutical (5.95%) - Innovent Biologics (5.29%) - Sinovac Biotech (5.11%) - BeiGene (4.91%) - Zhaoke Pharmaceutical (3.15%) [1]. Fund Manager Background - Zhao Wei, the fund manager, has a master's degree and extensive experience in the pharmaceutical and investment sectors - Previous roles include positions at GlaxoSmithKline, GF Securities, and China Merchants Fund Management - Zhao has managed various funds focused on healthcare and small-cap investments before joining Fuqua Fund Management in March 2021 [2].

证券代码：300765 证券简称：新诺威 公告编号：2025-054 石药创新制药股份有限公司 关于控股子公司 SYS6040 抗体偶联药物 获得美国药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、概述 石药创新制药股份有限公司（以下简称"公司"）的控股子公司石药集团巨石 生物制药有限公司（以下简称"巨石生物"）于近日收到美国食品药品监督管理 局（以下简称"FDA"）通知，由巨石生物申报的注射用 SYS6040 药品临床试验 申请已获得美国 FDA 批准，可以在美国开展临床试验。现将相关情况公告如下： 二、药物的基本信息 药物名称：SYS6040 剂 型：注射剂 此前，SYS6040 已经于 2025 年 3 月获得中华人民共和国国家药品监督管理 局批准，可以在中国开展临床试验。具体内容详见公司刊登于巨潮资讯网（htt p://www.cninfo.com.cn）的《关于控股子公司 SYS6040 抗体药物偶联物获得药 物临床试验批准通知书的公告》（公告编号：2025-028）。 四、风险提示 申请事项：临床试验 IND 编号 ...

Group 1 - The core viewpoint of the news is the performance of the Zhongyin Innovation Medical Mixed C Fund, which has shown significant growth in its net value and returns over various time frames [1] - As of June 9, 2025, the latest net value of the fund is 1.9069 yuan, reflecting a growth of 3.75% [1] - The fund's one-month return is 17.56%, six-month return is 43.00%, and year-to-date return is 60.87%, with respective rankings of 159 out of 4686, 36 out of 4533, and 29 out of 4564 [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed C Fund account for a total of 70.44%, with the largest holdings being Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] - The fund was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in stock research and has held various positions in asset management companies before joining Zhongyin Fund Management in 2022 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in various time frames [1] - The latest net value of the fund is 2.7270 yuan, with a growth of 1.79% [1] - The fund's performance over the past month has yielded a return of 8.91%, ranking 96 out of 1025 in its category [1] - Over the last six months, the fund has achieved a return of 13.01%, ranking 146 out of 989 [1] - Year-to-date, the fund has returned 19.66%, ranking 96 out of 999 [1] Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant positions in companies such as Heng Rui Pharmaceutical (8.90%) and WuXi AppTec (5.12%) [1] - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [2]

金融界2025年6月9日消息，工银前沿医疗股票C(010685) 最新净值3.1120元，增长2.30%。该基金近1个 月收益率12.14%，同类排名57|1025；近3个月收益率17.88%，同类排名47|1010；今年来收益率 21.18%，同类排名83|999。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 来源：金融界 工银前沿医疗股票C股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8 ...

Economic Indicators - In May 2025, the U.S. added 139,000 non-farm jobs, exceeding the forecast of 126,000, while the unemployment rate remained stable at 4.2%[6] - The job vacancy rate has returned to pre-pandemic levels, indicating limited "buffer" for the labor market, which may lead to a faster increase in the unemployment rate[6] Market Reactions - U.S. stock markets surged, with the Dow Jones rising 443 points (1.05%) to close at 42,762 points, and the S&P 500 gaining 1.03% to 6,000 points, following positive employment data[10] - The European stock markets experienced slight gains, supported by the U.S. employment growth and an upward revision of the Eurozone's Q1 GDP to 0.6%[10] Currency and Commodity Trends - The U.S. dollar strengthened against major currencies, with the dollar index rising by 0.5%[28] - International oil prices increased, with NY crude oil up 1.9% to $64.58 per barrel, as concerns about demand suppression eased[28] Fixed Income Market - Following the employment data, U.S. Treasury yields rose by 9-13 basis points, indicating a sell-off in the bond market[5] - The 2-year Treasury yield increased to 4.03%, while the 10-year yield rose to 4.51%[31] Asian Market Performance - The A-share market showed mixed results, with the Shanghai Composite Index slightly up by 0.04% to 3,385 points, while the Shenzhen Component fell by 0.19%[17] - The Hong Kong market experienced declines, with the Hang Seng Index down 0.48% and the Hang Seng Tech Index dropping 0.63%[12] Sector Performance - In the U.S., all 11 sectors of the S&P 500 rose, with the energy sector leading gains, up nearly 2% due to improved oil demand outlook[10] - In Hong Kong, the materials sector gained 2.3%, while the information technology sector fell by 1.8%[13]

Group 1: Robotics and Manufacturing - The domestic general-purpose intelligent robot "Aibao" developed by Zhifang will be deployed in Dongfeng Liuzhou Automobile Factory for various intelligent operations, marking the first full-scene validation of a domestic embodied large model in automotive manufacturing [1] - This collaboration signifies a milestone in robotic technology innovation and reflects the direction of China's intelligent manufacturing, allowing workers to focus on higher-value tasks after robots take over repetitive labor [1] Group 2: Aviation and Transportation - The Guangzhou Baiyun International Airport T3 terminal project is nearing completion and is expected to be operational within the year, enhancing the airport's capacity to over 120 million passengers and 3.8 million tons of cargo annually [2] - The T3 terminal will position Guangzhou Baiyun International Airport as a key node in the Guangdong-Hong Kong-Macao Greater Bay Area's transportation network, providing a new growth point for the regional economy [2] Group 3: Tourism and Economic Impact - In the first five months of this year, Hong Kong welcomed approximately 20 million visitors, with mainland visitors increasing by about 10% and overseas visitors by 18% [3] - Major events in Hong Kong are expected to attract around 840,000 tourists, generating an estimated consumption of HKD 3.3 billion and an economic value added of HKD 1.8 billion [3] Group 4: Marine Economy - Guangdong Province's marine production value is projected to exceed CNY 2 trillion in 2024, maintaining its position as the highest in the country for 30 consecutive years, with a nominal growth of 5.4% year-on-year [4] - The marine economy contributes 14.1% to the regional GDP and accounts for 27.3% of the province's nominal economic growth, driving a 0.7 percentage point increase in regional economic growth [4] Group 5: Stock Market Performance - The Shenzhen Component Index closed at 10,183.70 points, down 0.19% on June 6 [5] - Notable gainers in the Shenzhen market included Xinnuo Wei and Haichen Pharmaceutical, both rising by 20%, while Longjin Tui saw a significant decline of 36.28% [6]

明日主题前瞻 1、军工 | 据证券时报，近日军贸领域利好催化不断。6月6日，巴基斯坦政府官方账号在社交媒体上宣布，巴基斯坦政府取得了多项重大外交成就，包括从 中国购买40架歼-35第五代隐身战斗机、空警-500预警机、红旗-19防空系统。此前，当地时间6月5日，印尼政府正就采购中国制造的歼-10战机进行可行性评 估。 点评：分析认为，若巴基斯坦订单落地及完成交付，将是中国首次出口第五代航空装备，标志着我国军贸向更高端、更高价值量产品跃升，从而打开新的巨 大市场空间。此外，此次订单标志着我国军贸从单一产品向信息化、体系化作战的"套餐"式订单逐步转化。预计未来在国际军贸市场上，将更具备市场竞争 优势。有利于上市公司营收空间扩容及盈利水平大幅度提升。随着建军百年目标临近，"十四五"进入收官之年，行业全面进入快速增长阶段。 2、核电 | 据观察者网，特朗普政府近日暂停了美国核设备供应商向中国发电厂出售产品的许可证。知情人士透露，美国商务部已向各公司发出禁令，暂停 核电站零部件和设备的出口许可。报道称，美国核设备供应商包括西屋电气和艾默生。其中，西屋电气的技术被广泛应用于全球400多座核反应堆，而艾默 生则为核工业提供 ...

Core Viewpoint - The article emphasizes the investment strategy of "buying primary assets in the secondary market," which is a value investment approach that can yield excess returns by identifying undervalued stocks that exhibit characteristics of primary market investments [2][5]. Group 1: Concept of "Buying Primary Assets in the Secondary Market" - The primary market serves as a "incubation ground" for capital, where investors support companies' growth from inception, while the secondary market acts as a "trading venue" where stock prices can be distorted by emotions and external factors [4][5]. - This strategy involves identifying companies engaged in value-creating activities such as technological research, mergers and acquisitions, and market expansion, but whose stock prices do not yet reflect their long-term value [5][6]. Group 2: Identifying Investment Opportunities - Key indicators for identifying suitable investments include significant asset restructuring, major technological breakthroughs, and the exploration of new business avenues [7]. - Investors should be cautious of "hype-driven" stocks that lack substantial investment in genuine growth initiatives, distinguishing between companies with real financial commitments and those merely riding trends [7]. Group 3: Market Mispricing and Management Insight - Look for stocks with price-to-earnings (PE) ratios below 70% of the industry average or market capitalizations below their replacement costs, as these may indicate mispricing [8]. - Assess management's "primary market thinking" by examining their professional backgrounds and the proportion of shares they hold, with a higher ownership stake (over 30%) suggesting stronger alignment of interests [9]. Group 4: Conclusion and Investment Philosophy - The essence of the primary market is "value discovery," while the secondary market offers opportunities for "price negotiation." The intersection of these two aspects can lead to excess returns [11]. - When observing a company investing heavily in research and development or acquiring assets at low prices while its stock price declines, it may present an opportunity to "buy primary assets in the secondary market" [11].